We shared data from the P2 Explore-CKD trial during a late-breaking oral presentation at #KidneyWk. The parallel reductions in systolic blood pressure & albuminuria underscore lorundrostat's potential to improve cardio-renal outcomes in this high-risk population. ir.mineralystx.com/news-events/...

If you’re attending #AHA25, stop by & connect with our Medical Affairs team to learn more about our focus on aldosterone biology in CRM diseases. 📍Booth #4216 And join us Saturday in Heart Theater 1 for a discussion on the unmet need in uncontrolled #hypertension. We hope to see you!

If you’re in #Houston for @asnkidney.bsky.social #KidneyWk, join us tomorrow in Grand Ballroom C at the Convention Center to catch our #latebreaking presentation. We hope to see you there! #Hypertension #CKD #KidneyCare

#Hypertension remains the leading modifiable risk factor for #CVD, despite decades of therapeutic efforts. Aldosterone dysregulation is increasingly recognized as a missing piece of the puzzle. Read: www.statnews.com/sponsor/2025... #CardioSky #NephSky

Our team was in #Detroit with Black Girls RUN! & Dr. John Flack who discussed health equity and how black women can prioritize healthy living. Mineralys is focused on improving outcomes for people with #hypertension, including high-risk populations, and was honored to be part of this event.

We will be presenting lorundrostat data from our Phase 2 Explore-CKD trial in a late-breaking session next month at @asnkidney.bsky.social #KidneyWk on Friday, November 7. Read our press release for details: ir.mineralystx.com/news-events/... #Hypertension #CKD #ClinicalData #MLYS

Our CEO spoke with @statnews.com about recent breakthroughs in understanding cardiovascular diseases and how targeting aldosterone could reshape #hypertension treatment. Read the Q&A here: www.statnews.com/sponsor/2025... #HighBloodPressure #CVD #CardioRenalMetabolic #MLYS #CardioSky #NephSky

Today we announced completion of enrollment in Explore-OSA, our Phase 2 #clinicaltrial examining the efficacy, safety & tolerability of lorundrostat in participants with #OSA & #hypertension. Topline results are anticipated in Q1 2026. Read: ir.mineralystx.com/news-events/... #CardioSky #NephSky

Hypertension or high blood pressure affects 1.4B people globally. It’s the most prevalent & modifiable risk factor of cardiovascular diseases. In the U.S., 70M+ people aged 30–79 years have uncontrolled #hypertension. #WorldHeartDay #HighBloodPressure ♥️

New WHO report finds 1.4 billion people live with #hypertension. Hypertension is the number one risk factor for: ‼️ Heart attack ‼️ Stroke and can lead to: ‼️ Chronic kidney disease ‼️ Dementia Get your blood pressure checked today! Learn more 👉 bit.ly/4nikP8v

In just 6 years, Mineralys advanced #lorundrostat, a potential first-in-class aldosterone synthase inhibitor, from concept to pivotal published trials in #hypertension and is now preparing for a pre-NDA meeting in Q4 2025. Learn more: www.thepharmaletter.com/pharmaceutic... #Innovation #MLYS

Our CEO spoke with ThePharmaLetter about Mineralys’ clarity of purpose, long-term vision, & the clinical opportunities for lorundrostat to treat #hypertension and other aldosterone-driven conditions. Read the interview: www.thepharmaletter.com/pharmaceutic... #CardiovascularDisease

Dr. Manish Saxena is presenting new subgroup analyses from our Launch-HTN trial of lorundrostat at the American Heart Association Hypertension Scientific Sessions. Details: ir.mineralystx.com/news-events/... #Hypertension25 #BloodPressure @ahascience.bsky.social

Today we closed the sale of additional stock shares in our underwritten public offering, bringing total gross proceeds to $287.5M. Funds will support clinical development of lorundrostat, R&D and manufacturing, & pre-commercial activities. Read: ir.mineralystx.com/news-events/... #Hypertension

Detailed results from the pivotal P3 Launch-HTN trial were published today in @jama.com, reinforcing lorundrostat’s efficacy in a real-world setting. Read our press release to learn more: ir.mineralystx.com/news-events/... #BloodPressure #Cardiology #Cardiosky #MLYS

Today we announced positive topline results from our Phase 2 Explore-CKD trial evaluating the safety and efficacy of lorundrostat in subjects with #hypertension and comorbid chronic kidney disease (CKD). Learn more: ir.mineralystx.com/news-events/... #MLYS #chronickidneydisease #biotech

Today we presented detailed results from our pivotal Ph3 Launch-HTN trial at #ESH2025, reinforcing the promise of lorundrostat as a new treatment approach for aldosterone driven #hypertension. Read our press release to learn more: ir.mineralystx.com/news-events/... $MLYS #bloodpressure